Consolidation of AML Therapy with Autograft and Allograft Procedures Does not Negate the Poor Prognostic Impact of FLT-3 Internal Tandem Duplications: Results for UK MRC AML 10 and 12 Trials.

Reviewer: Julie Draznin Maltzman, MD
Ultima Vez Modificado: 9 de diciembre del 2002

Translation for this article does not exist


7 Tips for Giving Smart on #givingtuesday
by Christina Bach, MSW, LCSW, OSW-C
November 25, 2015

Related News

Addition of Gemtuzumab Ozogamicin Ups Survival in AML

Apr 9, 2012

Phase 3 trial shows improved event-free, overall survival versus standard therapy alone

Azacitidine Treatment Effective in Previously Untreated AML

Jul 26, 2011

Better response rate for previously untreated patients, those with WBC count of <10 × 109/L

Specific Mutations in AML Affect Response to Therapy

Mar 15, 2012

Also, bone marrow cells in myelodysplastic syndromes, secondary AML are clonal